CTIC Resumes Trading

Cell Therapeutics announces Pixantrone “significantly increases” complete remissions, overall response rates, frequency of durable remissions and progression free survival (CTIC) 1.58 +0.15 : Co announces at the 2009 ASCO Annual Meeting for the first time since the top-line data were released, complete pivotal phase III results of CTI’s EXTEND clinical trial of pixantrone in relapsed or refractory aggressive non-Hodgkin’s lymphoma were presented by Principal Investigator, Ruth Pettengell, M.D. of St. George’s Hospital, University of London.

FREE Trend analysis for CTIC Here

Comment on this post below.